Stanislaw M Stepkowski

US Patent:

7365096, Apr 29, 2008

Filed:

Dec 9, 2003

Appl. No.:

10/731769

Inventors:

Robert A. Kirken - Conroe TX, US
Barry D. Kahan - Houston TX, US
Stanislaw M. Stepkowski - Pearland TX, US
Waldemar Priebe - Houston TX, US
Izabela Fokt - Spring TX, US
Szymon Kosinski - Menomonee Falls WI, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31/21
A61K 31/13
A61K 31/12
A61K 8/73

US Classification:

514513, 514 80, 514690, 514659, 424 49

Abstract:

Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e. g. , T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

US Patent:

7928062, Apr 19, 2011

Filed:

Nov 5, 2007

Appl. No.:

11/935147

Inventors:

Robert A. Kirken - El Paso TX, US
Barry D. Kahan - Houston TX, US
Stanislaw M. Stepkowski - Pearland TX, US
Waldemar Priebe - Houston TX, US
Izabela Fokt - Spring TX, US
Szymon Kosinski - Menomonee Falls WI, US

Assignee:

Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 38/00
A61K 31/12
A61K 31/13
A01N 35/00

US Classification:

514 11, 514690, 514659

Abstract:

Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e. g. , T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

US Patent:

20100003271, Jan 7, 2010

Filed:

Dec 17, 2007

Appl. No.:

12/518982

Inventors:

Stanislaw M. Stepkowski - Pearland TX, US

Assignee:

BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - AUSTIN TX

International Classification:

A61K 39/00
C12N 5/02

US Classification:

4241841, 435378

Abstract:

An ex vivo method of expanding a population of regulatory T-cells includes culturing a starting population of cells containing CD4CD25 T-cells in a growth medium; introducing nitric oxide into the growth medium sufficient to potentiate switching of the CD4CD25 T-cells to CD4CD25 regulatory T-cells (Treg cells), whereby a subpopulation of Treg cells is produced; and allowing the Treg cells to proliferate in culture, to provide a final population of T-cells containing more Treg cells than were present in the original T-cells. The resulting expanded population of Treg cells are used to deter or decrease an undesired T-cell mediated immune response, e.g., allograft rejection, in a mammalian host by transplanting the Treg cells at a site of a potential or existing undesired immune response, whereby the undesired immune response is deterred or decreased.

US Patent:

20130280208, Oct 24, 2013

Filed:

Jul 25, 2011

Appl. No.:

13/811778

Inventors:

Stanislaw M. Stepkowski - Sylvania OH, US
Wenhao Chen - Toledo OH, US
Yoshihiro Miyahara - Toledo OH, US

Assignee:

University of Toledo - Toledo OH

International Classification:

C12N 5/0783
A61K 35/14

US Classification:

424 852, 435325, 424 854, 424 9371, 435377

Abstract:

The present invention provides materials and methods related to culturing stable Treg cells or in vivo expansion of stable Treg cells, the cells made by the methods, treatments for various inflammatory/autoimmune pathologies and transplant/graft rejection, and related materials. Ex vivo induction and expansion of the stable Tregs is described, including use of inducing compositions, such as certain mAbs and other compounds, along with expansion medium comprising IL-2. In vivo expansion of stable Treg cells and treatments for various inflammatory/autoimmune pathologies and transplant/graft rejection are described, including the use of mAbs and their variants.

US Patent:

58830820, Mar 16, 1999

Filed:

Nov 23, 1994

Appl. No.:

8/344155

Inventors:

C. Frank Bennett - Carlsbad CA
Stanislaw M. Stepkowski - Houston TX

Assignee:

ISIS Pharmaceuticals, Inc. - Austin TX
Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 2104
A61K 4800

US Classification:

514 44

Abstract:

Compositions and methods are provided for the prevention and treatment of allograft rejection. Compositions are provided which comprise an antisense oligonucleotide targeted to a nucleic acid sequence encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, or endothelial leukocyte adhesion molecule-1 in combination with an immunosuppressive agent. Methods of preventing or treating allograft rejection by treating an allograft recipient with such a composition are provided. Methods for preventing allograft rejection comprising perfusion of the graft are also provided.

US Patent:

60512326, Apr 18, 2000

Filed:

Apr 15, 1997

Appl. No.:

8/842656

Inventors:

Rafik R. Ghobrial - Pearland TX
Stanislaw M. Stepkowski - Houston TX
Barry D. Kahan - Houston TX

Assignee:

Board of Regents, University of Texas System - Austin TX

International Classification:

A61K 39385
C07K 14705
C07K 14745

US Classification:

4241921

Abstract:

Chimeric MHC Class I molecules having a recipient-type N-terminus, a donor-type alpha-1 helical region, and a recipient-type alpha-2 domain induce tolerance to donor grafts when administered to the recipient at time of transplantation.